News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 06 - 18

Efung Dynamics | Continuously Doubling Down on the World's First Red Blood Cell Innovation Track! Ef

Recently, Westlake Therapeutics (Hangzhou) Co., Ltd. (hereinafter referred to as "Westlake Therapeutics") announced the completion of a new financing round exceeding RMB 100 million. This round was co-led by Beijing Shijingshan Modern Innovation Industry Development Fund Co., Ltd. ("Shijingshan Modern Innovation Industry Fund") and Ruili Synthetic Biology Fund, with follow-on participation from renowned industrial investors. Existing shareholders including Efung Capital, Huafang Capital, and Sequoia China continued to inject additional capital.The proceeds from this financi...

浏览次数：3

查看详情>>

发布时间: 2026 - 06 - 17

Efung Honor | Efung Capital Named Among 36Kr's 2026 "China Equity Investment Industry Venture Capita

Recently,36Kr's 2026 annual"China Equity Investment Industry Investment Institutions" series rosterwas officially released, with Efung Capital honored as one of the"China Equity Investment Industry Venture Capital Institutions,"and the Waves·2026 "36 Under 36" rosterwas officially announced,with Efung Capital's Zhu Pai named to the list.At the outset of 2026, McKinsey made a judgment in its global private market report: Alpha is no longer found—it is made. Persistently low interest rates, ever-inflating valuation multiples, and readily available cheap...

浏览次数：2

查看详情>>

发布时间: 2026 - 06 - 16

Efung Mingyuan Seed Fund Lands in Guangming, Focusing on "20+8" Biomedical and High-End Medical Devi

June 10, 2026Shenzhen Efung Mingyuan Seed Venture Investment Partnership (Limited Partnership), established with equity participation from the Shenzhen Science and Technology Innovation Seed Fund, officially completed its business registration.This milestone marks a critical step forward for Efung Capital in ultra-early-stage investment, and more importantly, signals that Shenzhen's "20+8" industrial clusters have welcomed a new seed fund force that deeply integrates "industrial capital with cutting-edge scientific research."01Precisely Targeting the "20+8" In...

浏览次数：4

查看详情>>

发布时间: 2026 - 06 - 11

World's First Oral Solid Microtubule Stabilizer Receives Phase III Clinical Approval! Breakthrough f

Beijing, China, June 11, 2026 — Beijing Biostar Pharmaceuticals Co., Ltd. (hereinafter referred to as "Biostar", stock code: 2563.HK), a biopharmaceutical company leveraging a synthetic biology R&D platform to focus on developing proprietary anticancer drugs, today announced that its core pipeline product, utidelone capsules (UTD2), has received clinical trial approval (Notice No.: 2026LP01769) from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III clinical study (BG02-2601) in the treatment of HER2-negative advanced breast ...

浏览次数：4

查看详情>>